Stay updated on Taldefgrobep Alfa in SMA Clinical Trial
Sign up to get notified when there's something new on the Taldefgrobep Alfa in SMA Clinical Trial page.

Latest updates to the Taldefgrobep Alfa in SMA Clinical Trial page
- Check3 days agoChange DetectedThe ClinicalTrials.gov record for the spinal muscular atrophy study is available, with details on its Phase 3 design, treatment arms, eligibility, locations, and measured outcomes. The study is listed as active but no longer recruiting.SummaryDifference71%

- Check10 days agoChange DetectedThe footer’s displayed site revision changed from v3.7.2 to v3.8.0. The study record still shows a 403 Forbidden error.SummaryDifference0.2%

- Check17 days agoChange DetectedA site-wide NIH notice announces updates and explains a transition in terminology from “Artificial Intelligence” to “Super Intelligence” across NIH content.SummaryDifference1%

- Check24 days agoChange DetectedThe footer’s ClinicalTrials.gov revision label changes from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check31 days agoChange DetectedThe footer revision indicator changed from v3.7.0 to v3.7.1; the study page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check53 days agoChange DetectedThe page now shows a 403 Forbidden error instead of the study record, with the addition of 403-related header text and boilerplate. The deletions remove study-content sections, suggesting restricted access or a page failure rather than new information.SummaryDifference18%

Stay in the know with updates to Taldefgrobep Alfa in SMA Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Taldefgrobep Alfa in SMA Clinical Trial page.